Novo Acquires Xellia Pharmaceuticals for $700 Million


May 22, 2013

PharmaTimes Online

Novo A/S, the holding company of Denmark's Novo Nordisk, has acquired Xellia Pharmaceuticals of Norway in a deal valued at $700 million.

Xellia was spun-out from Alpharma in 2008 and was principally owned by UK equity group 3i. It specializes on anti-infective products for multi-drug resistant infections and is "a world-leading supplier of vancomycin and colistimethate sodium." Read the full story
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments